Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Lava Therapeutics, a Netherlands-based cancer immunotherapy developer based on research at Amsterdam University Medical Centers, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2016, Lava is developing bispecific antibody-based treatments intended to treat cancer by activating a subset of T cells known as the Vg9Vd2 cells, which can…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.